



Earn CLE Credits*

*PENDING APPROVAL

HYBRID EVENT

PCC | Pharmaceutical Compliance Congress

IN-PERSON EXPERIENCE:

APRIL 25-27, 2022

THE RITZ-CARLTON, TYSONS CORNER • MCLEAN, VA

VIRTUAL EXPERIENCE: MAY 3-4, 2022

INDUSTRY'S LEADING BIO/PHARMA EVENT FOR COMPLIANCE AND LEGAL PROFESSIONALS



ANN BEASLEY

Chief Compliance Officer,
Zai Lab



BETH HOLLY

Chief Compliance Officer,
Regeneron



CYNTHIA CETANI

Chief Integrity &
Compliance Officer,
Indivior



JAKE DEBOEVER

Vice President,
Chief Compliance Officer,
Dermavant Sciences



LING ZENG

Chief Legal Officer,
Dicerna



TARA D'ORSI

Executive Vice President, Chief
Compliance Officer and General Counsel,
Kyowa Kirin North America



DAVID RYAN

Vice President and
Chief Compliance Officer,
Epizyme



JIM STANSEL

Executive Vice President, General
Counsel and Corporate Secretary,
PhRMA

Platinum Sponsors



Gold Sponsor



[INFORMACONNECT.COM/PCC](https://informaconnect.com/PCC) • [#PCC2022](https://twitter.com/PCC2022)



EVENT EXPERIENCE

Held during the long-standing April timeframe, PCC provides progressive insights from the world's most experienced compliance and legal professionals on the issues that matter for 2022. Delivered in a hybrid format, hear critical policy, regulatory and enforcement updates, benchmark winning frameworks and collaborate on best practices for compliance excellence in the year ahead.

ALL ACCESS EXPERIENCE — APRIL 25-27 | MCLEAN, VA

- Unite with industry peers at this three day in-person offering fit with keynote presentations and innovative case studies
- Enjoy networking, benchmarking and idea sharing face-to-face to further enhance compliance efforts
- Customize your experience through tailored breakouts on hot topics
- Attend the highly acclaimed CCO and GC summit luncheon
- Participate in the thought-provoking Diversity, Equity and Inclusion Summit
- **PLUS!** All benefits included in the virtual experience pass

VIRTUAL EXPERIENCE — MAY 3-4 | CONNECTME VIRTUAL PLATFORM

- The week following the in-person offering, benefit from two days of virtual content featuring new presentations
- Live Q&A with industry thought-leaders
- On-demand access to recorded sessions from many of the in-person presentations and panels — Available for 10 business days
- Event platform with dynamic features including attendee and company profiles, advanced search capabilities to identify opportunities and potential partners, easy-to-use technology to enable virtual networking, seamless scheduling tools to establish meeting times

PAST ATTENDEE ACCLAIM FROM OUR FIRST HYBRID EVENT


“Very informative and engaging speakers, panelists and moderators. Relevant topics and good mix of pharma, law firms, consultants and vendors/service providers. Event was very well run-in light of COVID situation.”

“This was my first PCC experience, and given the current state of the “world,” it was an extremely well-done conference.”


AUDIENCE INSIGHT

PCC is the Premier Conference for Staying on the Pulse of Enforcement Trends, Supercharging Your Best Practice Playbook and Expanding Your Network


WHO ATTENDS



COMPANY TYPE




80% OF LIFE SCIENCES PARTICIPANTS HAVE DISTINCT FUNCTIONAL EXPERTISE



**Compliance/
Ethics/Oversight**

KEY TITLES NOTED:

- CCO
- SVP Compliance & Privacy Officer
- Sr Director, Ethics & Business Integrity
- Global Chief Compliance Officer
- SVP, Chief Compliance & Risk Officer
- Sr Director, Compliance Monitoring




**Legal
Affairs**

KEY TITLES NOTED:

- General Counsel
- Exec VP, GC & Corporate Secretary
- Legal Counsel IP & Contracts
- Global Life Sciences Attorney
- VP, U.S. Legal Affairs & General Counsel
- Exec Director, Head U.S. Legal Bus. Services


PCC PAST IN-PERSON PARTICIPANT PROFILE



IN-PERSON EXPERIENCE

DAY ONE — MONDAY, APRIL 25, 2022

**Please note all times are listed in EDT*


7:00-8:00 AM	Conference Registration and Networking Breakfast
8:00-8:10 AM	Informa Connect Welcome and Chairman's Opening Remarks <i>Caitlin Murgia, PCC Program Director, Informa Connect</i> <i>John Patrick Oroho, Executive Vice President, Chief Strategy Officer, Porzio Life Sciences, LLC; Principal, Porzio, Bromberg & Newman, P.C.</i>
8:10-8:15 AM	Year in Review Video Reveal Presented by: 
8:15-9:00 AM	Why and How You Can EVOLVE Your Compliance Program <ul style="list-style-type: none"> • Reflections on when to refresh a compliance program to evolve with the business and healthcare marketplace • Lessons involved in developing a strategic True North for compliance in your organization • How to realign your compliance team to your True North • Lessons from developing change management plans and actions <i>Michael Shaw, Principal, Global Head of Risk and Compliance, ZS</i> <i>Beth Holly, Chief Compliance Officer, Regeneron</i>
9:00-9:30 AM	Futureproof Your Compliance Function: Process, People, and Technology During this innovative keynote session, hear how technology is evolving the bio/pharma industry and what this digital advancement means for compliance teams. <i>Katherine Buckley, Partner, Pharmaceutical & Life Sciences; Risk & Regulatory Leader, PwC</i> <i>Brian Riewerts, Partner, Pharmaceutical and Life Sciences; Risk & Regulatory Leader, PwC</i>
9:30-10:00 AM	PhRMA Update <i>Delivered by: Jim Stansel, Executive Vice President, General Counsel and Corporate Secretary, PhRMA</i>
10:00-10:30 AM	Networking and Refreshment Break
10:30-11:00 AM	PANEL Building a Compliance Program and Educating Internal Stakeholders to Gain Alignment, Support and Ownership MODERATOR: Terra Buckley, Vice President, Head of MedPro Compliance Advisory Services, MedPro Systems, LLC PANELISTS: Ann Beasley, Chief Compliance Officer, Zai Lab <i>Jeremy Lutsky, Senior Legal Counsel & Head of Compliance, PhaseBio</i> <i>Emily Gainor, Senior Director, Corporate and Compliance Counsel, Ironwood Pharmaceuticals</i> <i>Christie Camelio, Chief Compliance and Risk Officer, EQRx</i>
11:00 AM-12:15 PM	PANEL Keynote Enforcement Panel — Stay on the Pulse of Emerging Trends <ul style="list-style-type: none"> • Zero in on the regulators emerging areas of focus and discuss recent trends in enforcement oversight (speaker programs, R&D, EHR, patient support/assistance and more) • Discover top priorities for 2022 on the DOJ's radar MODERATOR: Melissa Tearney, Department Co-Chair, Litigation, Choate Hall & Stewart PANELISTS: Clint Narver, Assistant Director, Consumer Protection Branch, U.S. Department of Justice (DOJ) <i>Tom Corcoran, Chief Civil Division, U.S. Attorney's Office for the District of Maryland</i> <i>Paul Kaufman, Assistant U.S. Attorney, U.S. Attorney's Office for the Eastern District of Pennsylvania</i> <i>Amanda Masselam Strachan, Assistant U.S. Attorney and Chief, Health Care Fraud Unit, U.S. Attorney's Office for the District of Massachusetts</i> <i>Lee M. Cortes, Executive Assistant U.S. Attorney, United States Attorney's Office for the District of New Jersey</i>



12:15-1:15 PM	Networking Luncheon		
12:15-1:15 PM	Highly-Acclaimed CCO and GC Summit Luncheon* The CCO and GC Summit provides world-class thought-leadership and is designed to deliver high-quality information that C-suite leaders can develop into an action plan. Collaborate with your distinguished colleagues to gain valuable insights through an interactive and engaging working group. <i>Sujata Dayal, Vice President & Global Chief Compliance Officer, Medline Industries, Inc.</i> To reserve your seat, email Matt.Hannon@informa.com <i>*Informa Connect reserves the right to qualify participants for this Summit. Attendees must be a CCO, VP or GC and currently employed by a life sciences manufacturer.</i>		
1:15-3:00 PM	ATTENDEES CHOOSE FROM THREE TRACKS (1-3)		
	TRACK 1 Patient and Advocacy Compliance – A Look at Key Program Oversight, Interaction Risks and Enforcement Trends 1:15 Optimize Advocacy-Compliance Interactions by Minimizing Barriers and Enhancing Successful Partnerships <i>Christopher Canada, Esq., Executive Director Compliance, Amicus Therapeutics</i> <i>Amanda Sowinski, Senior Manager, Patient & Professional Advocacy, Amicus Therapeutics</i> 1:45 Manufacturer Sponsored Patient Assistance Programs and Impact on Best Price: Compliance and Mitigation Strategies This session addresses Best Price reporting matters relevant to the CMS Final Rule scheduled for implementation January 1, 2023. Discuss emerging interpretations of compliance with the Final Rule and hear strategies to mitigate Best Price exposure for affected drug brands. <i>Richard A. Ford, MBA, FLMI, SICS, President, Biocel Access Solutions</i> 2:15 Spotlight on Rare Disease Compliance Risks <i>Danielle Pelot, Partner, Choate Hall & Stewart</i> <i>Kelly Pitt, Vice President, U.S. General Counsel, MorphoSys US Inc.</i> <i>Stephen Bychowski, Senior Corporate Counsel, Sanofi Genzyme</i> <i>Michael Hercz, Senior Vice President & General Counsel, Sentyln Therapeutics, Inc.</i>	TRACK 2 Auditing, Monitoring and Advanced Data Analytics 1:15 Enforcement Update <i>John Claud, Assistant Director, Corporate Compliance and Policy Unit, Consumer Protection Branch, U.S. Department of Justice (DOJ)</i> 1:30 Innovative Risk-Based Auditing and Monitoring Models MODERATOR: Johan Holm, Principal, Commercial Compliance, IQVIA PANELISTS: Abe Kassis, Global Head, Ethics and Compliance, Bausch Health Companies <i>Bjoern Dupre, Director Compliance Monitoring and Investigations, Bayer U.S. LLC</i> <i>Sean Hickson, Head, Auditing/Monitoring and Data Analytics, Novartis Pharmaceuticals Corporation</i> 2:00 Key Oversight Areas for Critical Compliance Insights from Sales to Patient Support MODERATOR: Mark Scallon, Principal LLP, Baker Tilly US LLP PANELISTS: Karen Lowney, Head of the Office of Ethics & Compliance (OEC), Sun Pharmaceutical Industries, Inc. <i>Tiffany Tang, Senior Director, Compliance, Covis Pharma</i> <i>Samantha Brabrant, Experienced Manager, Baker Tilly US LLP</i> 2:30 Transforming Advanced Analytics into Reality MODERATOR: John Poulin, Chief Technology Officer and Partner, Helio Health Group PANELISTS: Rachel Batykefer, Senior Director, Integrity & Compliance Operations, Mallinckrodt Pharmaceuticals <i>Holly Kramen, Former Vice President, Legal and Compliance, G1 Therapeutics, Inc.</i> <i>Michele Girdharry, Executive Director, Compliance, Amryt Pharma</i>	TRACK 3 Compliance in the Digital Age 1:15 Social Media – Risks vs Benefits <i>Brian Van Hoy, Vice President of Compliance, G&M Health LLC</i> 1:45 Must-Have Technologies and Skills your Compliance Function Needs to Drive Success MODERATOR: Erinn Hutchinson, Partner, Pharmaceutical and Life Sciences, PwC PANELISTS: Baris Goc, Director, Compliance Solutions, PwC <i>Ash Aggerwal, Senior Director, Compliance Excellence & Transformation, Astellas Pharma</i> <i>Gus Papandrikos, Executive Director, Daiichi Sankyo</i> 2:15 Industry Benchmarking and Best Practice Sharing for Navigating Digital Initiatives Across the Organization MODERATOR: Jonathan Greenblatt, Vice President of Legal, LinkSquares PANELISTS: Peter Agnoletto, Compliance Officer, General Medicines and Consumer Healthcare, North America Ethics & Business Integrity, Sanofi US <i>Eugenia Blackmon, Executive Director, Global Social Media and Digital Health, AbbVie</i> <i>Vahan Minassian Director, Digital Compliance, Pfizer</i> <i>Jessie Bustamante, General Counsel, ProPharma Group</i>
3:00-3:30 PM	Networking and Refreshment Break Hosted by: 		






3:30-4:10 PM	ATTENDEES CHOOSE BETWEEN TWO BREAKOUTS (A-B)	
	Oversight and Best Practices for Speaker Programs, HCP Engagement and Sales Interactions <i>Catherine (Cate) St. John, Senior Corporate Counsel, Sanofi US</i> <i>Cynthia Cetani, Chief Integrity & Compliance Officer, Indivior</i> <i>Rore Middleton, Senior Director, Compliance & Privacy, Blueprint Medicines</i> <i>Emily Gainor, Senior Director, Corporate and Compliance Counsel, Ironwood Pharmaceuticals</i>	Examination and Application of Key Learnings from Industry's Most Recent CIAs <i>Nikki Reeves, Partner, King & Spalding LLP</i>
4:15-5:00 PM	ATTENDEES SELECT FROM TWO INTERACTIVE SESSIONS BASED ON COMPANY SIZE (I-II)	
	EMERGING AND SMALL COMPANIES MODERATOR: <i>Jean McKiernan, Partner, Dovetail Consulting Group</i> PANELISTS: <i>Jake DeBoever, Vice President, Chief Compliance Officer, Dermavant Sciences</i> <i>Jeremy Lutsky, Senior Legal Counsel & Head of Compliance, PhaseBio</i> <i>Hunter Murdock, Executive Vice President, Legal & Compliance, Axsome</i>	MID-LARGE COMPANIES Effective Compliance – What Does that Mean? Explore what it means for mid-large pharmaceutical manufacturers to have an effective compliance program in the eyes of regulators: <ul style="list-style-type: none"> • What are enforcement agencies' expectations for mid-sized and larger companies? • How do you demonstrate that you have a culture of compliance? • In-depth discussion on developing policies, training, communications, auditing and monitoring that "work in practice" • What's next? What proactive steps should we be taking now? <i>Jon Wilkenfeld, President, Potomac River Partners</i> <i>Lori Kagan, Executive Director, North American Compliance, Kyowa Kirin, Inc.</i> <i>Eric J. Bottelier, NA Regional Lead, Ethics & Compliance Officer, CSL Behring</i> <i>Dobson Schofield, Head, E&C Global Medical and GPLS, Global Portfolio Division, Takeda</i>
5:00	 Cocktail and Networking Reception Hosted by: CHOATE	

DAY TWO – TUESDAY, APRIL 26, 2022

**Please note all times are listed in EDT*

8:00-8:30 AM	Industry-Only Breakfast Solution Summit Hosted by:  Lextegrity <i>Verity Blair, Enterprise Account Executive, Lextegrity</i> <i>Parth Chanda, CEO and Founder, Lextegrity</i>
8:30-8:45 AM	Chairman's Review of Day One <i>John Patrick Oroho, Executive Vice President, Chief Strategy Officer, Porzio Life Sciences, LLC; Principal, Porzio, Bromberg & Newman, P.C.</i>
8:45-9:15 AM	Compliance Top 10 – Clear and Concise Overview of the Top Areas of Concern for the Compliance Professional Kick-off the meeting with a critical rundown of the timeliest topic areas every compliance professional should have on their radar for a successful year ahead. <i>John Patrick Oroho, Executive Vice President, Chief Strategy Officer, Porzio Life Sciences, LLC; Principal, Porzio, Bromberg & Newman, P.C.</i>





9:15-10:15 AM	CCO Innovation Panel <ul style="list-style-type: none"> • Discuss what the “new normal” looks like for compliance and legal teams and how culture has been impacted by the pandemic • Address emerging high-risk areas garnering enhanced oversight within the organization • Share innovative strategies for collaborating with business partners • Benchmark on the future of virtual and digital engagement and operations moving forward • Assess Environmental, Social and Governance (ESG) risks and the role of compliance MODERATOR: Justin Will, Global Commercial Compliance Consulting & Managed Services Practice Leader, IQVIA PANELISTS: Cynthia Cetani, Chief Integrity & Compliance Officer, Indivior David Ryan, Vice President and Chief Compliance Officer, Epizyme Greg Moss, Executive Vice President, General Counsel, Kadmon, a Sanofi Company; Former Chief Compliance Officer, Kadmon Daryl Kreml, Vice President, Chief Compliance Officer, Sage Therapeutics	
10:15-10:45 AM	Networking and Refreshment Break	
10:45-11:30 AM	Risk Insights and Monitoring – An Enforcer’s Landscape As a life sciences company, understanding the key risk indicators when engaging with HCP/Os and monitoring your speaking engagements and associated data is critical. Without a comprehensive monitoring and analytics strategy, your organization is missing valuable insights and potentially opening itself to major enforcement risk. During this session, hear recent enforcement actions, how those enforcements may impact future engagements, what key risk indicators companies should be watching closely and how to build a forward-looking monitoring/analytics tool. Tim Robinson, Chief Legal and Privacy Officer, MediSpend Seth Houston, Chief Commercial Officer, MediSpend	
11:30 AM-12:30 PM	Former Prosecutor Spotlight – Hear an In-Depth Assessment and Forecast of Enforcement Activity Impacting the Life Sciences Marketplace <ul style="list-style-type: none"> • Gain a unique view from professionals who have served as a representative of the U.S. government and are now outside counsel • Share key takeaways from recent high-profile cases to mitigate risk moving forward MODERATOR: Ernie Hernandez, Vice President and Chief Compliance Officer, GBT PANELISTS: Rachael Honig, Former Acting U.S. Attorney, U.S. Attorney’s Office for the District of New Jersey George Varghese, Partner, WilmerHale LLP; Former Assistant U.S. Attorney, U.S. Attorney’s Offices for the District of Massachusetts and the District of Columbia Nathaniel Mendell, Partner, Morrison & Foerster LLP; former Acting U.S. Attorney, U.S. Attorney’s Office for the District of Massachusetts	
12:30-1:30 PM	Networking Luncheon	
1:30-2:15 PM	ATTENDEES CHOOSE FROM THREE BREAKOUTS (A-C)	
	A. Operationalizing the OIG Special Fraud Alert on Speaker Programs MODERATOR: Marci Juneau, Partner, Helio Health Group PANELISTS: Hannah Putnam, Senior Ethics & Compliance Officer, Fresenius Medical Care North America Daina Selvig, Vice President, Legal & Chief Compliance Officer, ARDELYX INC. Sarah Whipple, Chief Compliance Officer, Akebia Therapeutics Andrea Kocharyan, Vice President, Head of Legal and Compliance, Zealand US, Inc. Averi Price, former General Counsel, Chief Compliance Officer, Radius Health Ernie Hernandez, Vice President and Chief Compliance Officer, GBT	B. Clinical and R&D Trends Meena Datta, Partner, Sidley Austin LLP
		C. Conducting Risk Mapping and a Risk Assessment Tara D’Orsi, Executive Vice President, Chief Compliance Officer and General Counsel, Kyowa Kirin North America Regina Alvarado, Principal, US Commercial Compliance Consulting Lead, Global Commercial Compliance Consulting, IQVIA Heather Golding, Former General Counsel and Chief Ethics & Compliance Officer, Sobi NA Maria Ostrovsky, Vice President, Chief Compliance Officer, Associate General Counsel, Deciphera Pharmaceuticals





2:15-3:00 PM	ATTENDEES CHOOSE FROM THREE BREAKOUTS (D-F)		
	<p>D. Drug Pricing and State Transparency Updates</p> <p><i>Katherine Chaurette, Senior Vice President, Healthcare Law & Compliance, Blueprint Medicines</i></p> <p><i>Chris Sloan, Associate Director, Market Access Marketing, Blueprint Medicines</i></p>	<p>E. Global Compliance Considerations and Trends</p> <p><i>Richard Hodgins, Chief Commercial Officer, Technology, Intuition</i></p> <p><i>Melanie Polloway, Executive Director, Daiichi Sankyo Inc.</i></p>	<p>F. A Look at Commercial and Medical Affairs to Understand Changes to an Organization's Evolving Compliance Needs</p> <p><i>David Ryan, Vice President and Chief Compliance Officer, Epizyme</i></p> <p><i>Jake DeBoever, Vice President, Chief Compliance Officer, Dermavant Sciences</i></p> <p><i>Amy Wilson, Vice President, Chief Compliance Officer, Esperion</i></p> <p><i>Ed Sleeper, Ethics and Compliance Officer, HUTCHMED International Corporation</i></p> <p><i>Joy Dowdle, Partner, Litigation Department, Paul Hastings</i></p>
3:00-3:30 PM	Networking and Refreshment Break		
3:30-4:15 PM	ATTENDEES CHOOSE FROM TWO BREAKOUTS (G-H)		
	<p>G. From the Ground Up – Building and Implementing a Privacy Management Strategy</p> <p>With the continued increase in privacy and data protection regulation across the globe, companies may be considering formalizing or optimizing their data-related risk management efforts. Attend this session for an exploration of real industry experiences and learnings, including:</p> <ul style="list-style-type: none"> • Various privacy management governance models • Techniques to earn and drive executive stakeholder support and organizational buy-in • Examples of communications and awareness strategies and creative tactics • Using program metrics to drive privacy risk management and program maturity <p><i>Kris Hall, Managing Director, Dovetail Consulting Group</i></p> <p><i>Raegan McClain, Chief Compliance Officer, Oyster Point Pharma, Inc.</i></p>	<p>H. Advertising, Promotion and Communication Strategies for Biologics, Biosimilars, and Interchangeable Biosimilars</p> <p>With the first approvals of Interchangeable Biosimilars by FDA, significant markets are at stake for drugs that treat serious medical issues, and considering the potential for biosimilars to result in significant cost savings to healthcare systems, the competition is gearing up for promotion in a largely untested regulatory environment. We will explore product communications issues from the perspective of the innovator Reference Biologic Drug as well as the Biosimilar or Interchangeable Product. We will review:</p> <ul style="list-style-type: none"> • FDA's Draft Guidance on biosimilar promotion • OPDP Untitled Letter on Neulasta • The potential impact of the 2021 Final Rule on "Intended Use" • The potential role of FDA's Scientific Exchange, Consistent with FDA Label, and Payor Guidance • Potential frameworks for Interchangeable Biosimilar promotion • How to incorporate these issues into an effective Compliance Program <p><i>Craig Bleifer, Partner, Akin, Gump Strauss, Hauer & Feld LLP</i></p> <p><i>Timothy Roberts, Vice President, Chief Compliance Officer, Amneal Pharmaceuticals</i></p>	





4:15-5:00 PM	ATTENDEES CHOOSE FROM TWO BREAKOUTS (I-J)	
	<div>I. Reduce Compliance Risk Using a Continuous Learning Approach In this session, hear practical approaches to implementing continuous learning in your company, even with a limited compliance training budget. Topics include:<ul style="list-style-type: none">• A simple formula for continuous learning• Creating core training that that doesn't put your learners to sleep• Implementing targeted reinforcement training for higher risk areas• Using quick reference guides and other tools for just-in-time knowledge support<i>Dan O'Connor, Senior Vice President, PharmaCertify, NXLevel Solutions</i> <i>Ed Sleeper, Ethics and Compliance Officer, HUTCHMED International Corporation</i> <i>Dhara Moro, Associate Director, Compliance Operations, Sage Therapeutics</i> <i>Jennifer Garon, Senior Manager, Global Compliance Operations, Sarepta Therapeutics</i></div>	<div>J. Break Down the Silo: How to Integrate Your Total Business Risk during M&A <i>Anthony Greco, Director, Pharmaceutical & Life Sciences; Risk & Regulatory Consulting Services, PwC</i> <i>Laurel Saltiel, Manager, Pharmaceutical & Life Sciences; Risk & Regulatory Consulting Services, PwC</i></div>
5:00 PM	Networking Reception	
DAY THREE – WEDNESDAY, APRIL 27, 2022		
*Please note all times are listed in EDT		
8:00-9:00 AM	<div><div>Diversity, Equity and Inclusion Breakfast Summit Hosted by:<ul style="list-style-type: none">• Take action, be accountable and lead intentionally with inclusion• Work culture that emphasizes the importance of diversity and inclusion• Policies and procedures designed to change the dynamics of bias and foster equality• Innovative efforts driving empowerment enterprise-wide• Talent needs in the industry and how they are creating an ultracompetitive market• Leadership strategies and lessons learned to advance changeSPEAKER AND MODERATOR: Shannon Schuyler, Chief Purpose and Inclusion Officer, PwC PANELISTS: Christopher Moody, Ethics & Compliance Officer, Google Health, Google Sujata Dayal, Vice President & Global Chief Compliance Officer, Medline Industries</div><div></div></div>	
9:00-9:15 AM	Chairman's Review of Day Two <i>John Patrick Oroho, Executive Vice President, Chief Strategy Officer, Porzio Life Sciences, LLC; Principal, Porzio, Bromberg & Newman, P.C.</i>	
9:15-10:00 AM	Policy Reforms, Pricing Pressures and Payer Marketplace Changes Impacting the Life Sciences <ul style="list-style-type: none">• Evaluate current healthcare policies and rebate rules impacting the industry• Navigate drug pricing transparency and reporting on a state and federal level <i>Chris Sloan, Associate Director, Market Access Marketing, Blueprint Medicines</i> <i>Katherine Chaurette, Senior Vice President Healthcare Law and Compliance, Blueprint Medicines</i>	
10:00-10:30 AM	Networking and Refreshment Break	
10:30-11:15 AM	CMS Address <i>Veronika Peleshchuk Fradlin, Director, Division of Transparency Projects, Centers for Medicare & Medicaid Services (CMS)</i>	
11:15 AM-12:00 PM	FDA Address <i>Catherine Gray, Acting Director, Office of Prescription Drug Promotion (OPDP), U.S. Food and Drug Administration (FDA)</i>	
12:00 PM	Close of In-Person Programming	



VIRTUAL PROGRAMMING

DAY FOUR – TUESDAY, MAY 3, 2022

**Please note all times are listed in EDT*

10:00-10:05 AM

LIVE SESSION

Chairman's Welcome

John Patrick Oroho, Executive Vice President, Chief Strategy Officer, Porzio Life Sciences, LLC; Principal, Porzio, Bromberg & Newman, P.C.

10:05-10:15 AM

Year in Review Video Reveal Presented by: 

10:15-10:45 AM

LIVE SESSION

HCP Engagement – Cradle-to-Grave

Marty Healy, Principal, Porzio Bromberg & Newman
Isha Arora, Associate Vice President of Compliance Technology, Porzio Life Sciences, LLC

11:00 AM-5:00 PM

Take Time for Networking and Viewing On-Demand Content

DAY FIVE – WEDNESDAY, MAY 4, 2022

**Please note all times are listed in EDT*

11:00 AM-12:00 PM

LIVE SESSION

Industry Benchmarking Report Review and Zero-In on Key Trends for 2022

11:00 AM-5:00 PM

Take Time for Networking and Viewing On-Demand Content



Informa AllSecure

This event is produced to the Informa AllSecure Standard

Ten Priority Commitments at all Informa Events

Post COVID-19, all Informa events will be run in accordance with the AllSecure standard, applying the full range of recommendations wherever applicable and possible, but with a commitment to ten key priorities:

Cleaning and Hygiene

1



ENHANCED CLEANING:

All Informa events will undertake enhanced, deep cleaning before, during and after our events, working with venue partners to ensure the highest standards of hygiene and cleanliness. This includes continuous sanitisation throughout the course of an event, with a focus on high-touch areas such as door handles, restrooms and food and beverage areas.

2



PERSONAL HYGIENE: All Informa events will provide additional hand washing facilities and hand sanitising stations throughout the event space, encouraging all participants to regularly wash and disinfect their hands.

Physical Distancing

3



NON-CONTACT REGISTRATION: All Informa events will employ a system that facilitates non-contact registration for participants, including the availability of online registration.

4



PHYSICAL CONTACT: All Informa events will request that participants avoid physical contact, such as handshakes and embraces, promoting alternative ways to greet business partners. The exchange of printed materials, such as business cards and sales brochures, will also be discouraged, with digital alternatives recommended.

5



PHYSICAL DISTANCING: All Informa events will maintain a density of participants in line with local authority regulations and venue or other relevant guidance. This will be managed through one or more control measures such as pre-show communications to participants, a one-way traffic system around show floors, staggered and expanded entry times, on-site signage and floor markings and on-site physical distance ambassadors.

6



FOOD AND BEVERAGE STATIONS: All Informa event teams will work closely with venue partners to employ the highest standard of food safety, minimising self-service buffets in favour of pre-packaged food options or serviced buffets. If any queuing is anticipated, physical distancing will be maintained through the use of floor markings and relevant signage.

Detect and Protect

7



PERSONAL PROTECTIVE EQUIPMENT (PPE): Participants and staff at all Informa events will be asked to use items of PPE in line with local government and health authority advice. This may include wearing a face covering and the use of gloves or face screens in certain roles.

8



FIRST AID: All Informa events will have access to a qualified first aider and a separate isolation area if possible. Participants will be asked not to attend if they are feeling unwell, and teams will follow local health authority guidance on detecting and managing anyone who displays symptoms of COVID-19.

9



SCREENING: All Informa events will follow relevant health authority guidance on screening participants. This may include checking the temperatures of everyone on entry, through thermal scanning or other screening processes. Informa Connect Life Sciences requires all in-person attendees to show proof of vaccination against COVID-19.

10



TRACE AND CONTACT: Should it be necessary, all Informa events will work with local authorities to trace and contact participants at our events, subject to local privacy regulations.

CONGRESS SPONSORS & EXHIBITORS

Platinum Sponsors



PwC's Pharmaceutical and Life Sciences Industry Group is dedicated to helping deliver innovative solutions to the complex strategic, operational, and financial challenges facing pharmaceutical, biotechnology, and medical device companies. We offer a holistic set of digital products and services to help pharmaceutical and life sciences companies create an integrated, seamless experience for managing interactions with healthcare organizations/providers and patients while enabling global transparency reporting at scale.

For more information, visit us at www.pwc.com/us/pharma and <https://riskproducts.pwc.com/use-cases/pharmaceutical-life-sciences>



IQVIA Commercial Compliance is the industry's trusted name to deliver scalable, end-to-end technology solutions, strategic guidance and best in-class services, to effectively meet the demands of global compliance. Streamline and automate HCP/HCO interactions, efficiently manage global transparency reporting, mitigate risks, reduce costs, increase efficiencies and generate strategic insights from data to improve decision making.

Gold Sponsor



Founded in 1962, **Porzio, Bromberg & Newman** is a full-service law firm with 90 lawyers throughout offices in New York City, Washington, DC, Morristown, Ocean City, and Princeton, NJ, Westborough, MA and San Juan, Puerto Rico (Porzio, Bromberg & Newman (PR, LLC)). Porzio is committed to serving clients and achieving results through legal strategy, advocacy, technology and consulting services offered through the law firm and its three wholly-owned subsidiary companies. The firm provides legal services in the areas of employment,

litigation, bankruptcy and refinancing, white collar defense, governmental investigations, environmental, real estate, wealth preservation and tax planning, to companies from Fortune 500 corporations to start-up companies and public organizations and charities.

Porzio Life Sciences, LLC provides comprehensive commercialization and compliance solutions for Life Sciences companies at all stages of growth and development. A pioneer in the industry, Porzio Life Sciences offers services and software products that combine the law, compliance and life sciences business operations. Porzio Life Sciences' modular approach works to minimize risks and maximize efficiency for in-house compliance, legal and regulatory teams related to global, federal and state marketing and sales regulations, transparency reporting, supply chain licensing and third party HCP engagement.

Associate Sponsors



Supporting Sponsors



A GREAT PLACE TO MEET YOUR MARKET!

Maximize your access to decision-makers and align your brand with the life sciences industry's premier thought-leaders and industry innovators. Informa Connect's custom sponsorship programs are designed to support your organization's overall business development and marketing initiatives through meaningful prospect and customer interactions, brand assertion campaigns and content-rich thought-leadership opportunities. Capitalize on the life sciences community's premier platform for peer-to-peer exchange, solution driven content and first-in-class networking opportunities. For more information on how to position your company as a sponsor or exhibitor, contact:



Derek Tagliarino
212-600-3433
derek.tagliarino@informa.com

REGISTRATION

REGISTRATION FEE		STANDARD RATE
Life Sciences Companies	All Access Pass (In-Person + Virtual)	\$2799
	Virtual-Only	\$2299
Solution Providers/Consultants/Law Firms	All Access Pass (In-Person + Virtual)	\$3299
	Virtual-Only	\$2799

4 WAYS TO REGISTER NOW!



WEB

informaconnect.com/pcc



PHONE

+1-212-600-3408



LIVE CHAT

informaconnect.com/pcc



EMAIL

matt.hannon@informa.com

YOUR KEY POINTS OF CONTACT:



Content Development:

Caitlin Murgia

Program Director

caitlin.murgia@informa.com • +1-781-496-5514



Sponsorship & Exhibits:

Derek Tagliarino

Head of Sales, Compliance & Legal

derek.tagliarino@informa.com • +1-212-600-3433



Registration & Teams:

Matt Hannon

Sr. Professional Development Advisor

matt.hannon@informa.com • +1-212-600-3408

VENUE INFORMATION

The Ritz-Carlton, Tysons Corner

1700 Tysons Boulevard

McLean, VA 22102

Hotel Direct Line: +1-703-506-4300

ACCOMMODATIONS

For hotel room availability and direct booking links, please visit the conference website and select the [Pricing and Venue](#) tab. Rooms are limited and the discounted rate will expire in advance of the meeting, so please book early. All travel arrangements are subject to availability.

Media Partners:



INFORMACONNECT.COM/PCC • #PCC2022

